TENEX.AI, the AI-native cybersecurity company transforming security operations, today announced additional investment in its $27 million Series A funding round from DTCP. This follows previous closes led by Crosspoint Capital Partners, with full participation from Andreessen Horowitz (a16z), Shield Capital, DeepWork Capital, and the Florida Opportunity Fund. In just three quarters in the market, TENEX has exceeded $18 million in revenue and secured multiple Fortune 500 customers, underscoring TENEX’s leadership in the AI SOC and MDR markets. The investment supports its official expansion into the EMEA market, where TENEX anticipates establishing a physical international headquarters and scaling its EMEA team across 2026 to meet surging demand for AI-driven threat detection and response. Founded in 2015, DTCP is a global investment management firm with over €3 billion in assets under management and a team of more than 60 professionals across Europe, San Francisco, and Tel Aviv. DTCP backs the builders of the digital world — investing in the technologies and infrastructure that connect, compute, and power modern life. This partnership strengthens TENEX’s ability to deliver innovative, scalable security solutions tailored to EMEA enterprises facing evolving cyber threats. As part of this strategic funding, TENEX is officially entering the EMEA market, with plans to establish a dedicated physical international headquarters and rapidly expand its regional team throughout 2026. While location and further specifics will be announced in the coming months, the move signals TENEX’s ambitious vision to become a cornerstone of Europe’s cybersecurity landscape, leveraging the region’s robust tech ecosystem, regulatory frameworks like the EU AI Act, and collaborative initiatives such as the European Cyber Security Organisation (ECSO). This expansion not only enhances TENEX’s global footprint but also positions the company to address the unique cyber threats facing EMEA organizations, including converging threat groups as highlighted in the ENISA Threat Landscape 2025 report, rising ransomware attacks noted in Microsoft’s Digital Defense Report 2025, and the projected 12.42% CAGR growth in Europe’s cybersecurity market through 2033. By contributing to initiatives like ReArm Europe for collaborative R&D, TENEX aims to drive innovation, job creation, and resilient digital infrastructure across the continent. TENEX CEO Eric Foster announced: “This investment from DTCP propels our global mission forward, enabling us to bring AI-native MDR to the dynamic EMEA market. By establishing our international headquarters here, we’re tapping into Europe’s talent in AI and cybersecurity, while upholding the moral imperative to combat the evil of cybercrime and give good the advantage as we safeguard our allies’ critical infrastructure against sophisticated threats. With team growth across 2026 and exponential advancements in our U.S. operations, TENEX is committed to empowering businesses to innovate securely, fostering the next generation of cyber defenders on a worldwide scale.” TENEX’s alignment with the EMEA tech ecosystem is further evidenced by key 2025 trends, such as the World Economic Forum’s Global Cybersecurity Outlook emphasizing collaborative risk management, PwC’s identification of AI agents as a top trend for EMEA, and Aon’s insights on navigating cyber risks amid AI-driven competitiveness projects involving over 60 major European companies. These developments underscore the region’s momentum in fostering trustworthy AI and cybersecurity innovations, which TENEX is poised to advance through its agentic AI platform, integrating seamlessly with cloud-native environments to deliver unprecedented threat agility. This announced funding will accelerate TENEX’s engineering efforts to enhance its agentic AI capabilities, expand sales to meet growing international demand, and support its enterprise customers with faster, more cost-effective threat detection and response. “DTCP is thrilled to partner with TENEX as they pioneer AI-native security operations in EMEA and beyond,” said Lance Matthews, Partner at DTCP. “Their explosive growth and innovative approach to fusing AI with human expertise align perfectly with our focus on digital transformation, positioning them to redefine enterprise protection in a high-stakes landscape. We’re excited to support their EMEA expansion, which will leverage Europe’s AI talent and regulatory strengths to deliver scalable security solutions amid rising threats.” Source: https://tenex.ai/tenex-ai-dtcp-emea/

“We went through all sorts of configurations and designs,” Happi, co-founder and CEO of Exowatt, told TechCrunch. “They all look different from each other. We tried to learn from every one of them: How do I reduce structural costs? How do I reduce maintenance costs? How do I optimize for this?” After years of brainstorming and building, Exowatt’s first step toward that goal is a simple box the size of a shipping container topped with a clear awning. Inside is similarly simple. If Exowatt can deliver on its promise of delivering cheap solar power that generates electricity 24-7, it could upend the data center market and broader energy world, delivering round-the-clock power at very low cost. To scale production in pursuit of the one-cent per kWh target, Exowatt has raised an additional $50 million in an extension to its $70 million Series A round that closed in April, TechCrunch has exclusively learned. The extension was led by MVP Ventures and 8090 Industries with participation from Atomic, BAM, Bay Bridge Ventures, DeepWork Capital, Dragon Global, the Florida Opportunity Fund, Massive VC, New Atlas Capital, Overmatch, Protagonist, and StepStone. Previous investors include Andreessen Horowitz and Sam Altman. Source: https://techcrunch.com/2025/11/13/sam-atlman-backed-exowatt-wants-to-power-ai-data-centers-with-billions-of-hot-rocks/

Enhesa, the leading provider of regulatory business intelligence worldwide, today announced the acquisition of TotalSDS, a specialist provider of Safety Data Sheet (SDS) authoring software. The acquisition builds on Enhesa’s leadership position in product compliance, EHS intelligence and sustainable chemistry solutions. By integrating TotalSDS’ software and solutions, Enhesa will create an end-to-end workflow for the management of chemical safety data, allowing chemical manufacturers, formulators and distributors in the chemicals supply chain to stay compliant with complex and constantly changing global regulatory requirements. A pioneer in the field of software-driven SDS authoring and management, TotalSDS helps companies efficiently produce compliant chemical safety documentation and manage ongoing updates and dissemination of that documentation to key stakeholders. SDS are foundational building blocks to workplace safety containing detailed information on the chemical composition of products, including required disclosures on chemicals and chemical compounds that could harm workers. Currently, more than 83 countries require potentially harmful chemicals to be accompanied by SDS following a detailed standard for classification, labeling and record-keeping. Though many countries have adopted global requirements such as a Globally Harmonized System (GHS) for tracking and cataloging this information, details vary widely in each jurisdiction and reporting requirements are continually revised on a chemical-by-chemical basis. “SDS authoring and management is a complex, labor- and-detail-intensive process that many companies are still managing with printed documents stored in binders. Global regulatory reporting requirements demand that everyone in the hazardous chemicals supply chain should have the ability to produce and store real-time updates to their SDS based on changes in chemical formulation, hazard classification and different regional regulatory requirements – that is not something that can be reliably tracked on paper,” said Peter Schramme, CEO at Enhesa. “TotalSDS has pioneered the digital transformation of the SDS workflow, and that expertise is the perfect complement to our market-leading regulatory content and hazard intelligence.” Source: https://www.enhesa.com/resources/press/enhesa-acquires-totalsds/

This follows the initial close led by Crosspoint Capital Partners, with full participation from Andreessen Horowitz (a16z) and Shield Capital. In just six months in the market, TENEX has exceeded $10 million in revenue and secured multiple Fortune 500 customers, underscoring TENEX’s leadership in the AI SOC and MDR markets. The investment supports its commitment to establishing its world headquarters in Sarasota, FL, aligning with regional initiatives to bolster Florida’s already strong cybersecurity ecosystem. DeepWork Capital, an Orlando-based early-stage venture capital firm founded in 2015, invests in innovative companies in the technology and life science sectors through both proprietary and public committed capital funds. The Florida Opportunity Fund, a state-backed initiative promoting economic growth through targeted investments, has approved over $250 million in loans and investments for Florida businesses via programs like SSBCI 2.0. Together, these investors strengthen TENEX’s ties to Florida’s innovation landscape. As part of this investment, TENEX is opening its world headquarters in Sarasota, FL, in alignment with the emergence of CyberBay – Tampa Bay’s thriving cybersecurity ecosystem that ties together workforce development, the private sector, and military and government initiatives. Recent CyberBay milestones include an inaugural conference hosted by Cyber Florida, the Bellini College of Artificial Intelligence and Cybersecurity at USF, and Bellini Capital. The October event followed the historic $40 million gift that established the Bellini College earlier this year. TENEX anticipates hiring up to 100 high-skilled AI and cybersecurity employees in Sarasota over the next couple of years, with proportional growth in its other offices in Kansas City, and San Jose, CA. Source: https://tenex.ai/tenex-florida-opportunity-fund-sarasota-headquarters/?v=li

Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies that modulate molecular motor proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MT-125 for the treatment of glioblastoma (GBM). Fast Track is an FDA program designed to facilitate development and expedite review of drugs that treat serious conditions and address unmet medical needs. This designation benefits patients and drug sponsors by enabling more frequent interactions with the FDA and providing eligibility for rolling review of a marketing application. "Receiving Fast Track designation validates our conviction that MT-125 has the potential to offer an entirely novel treatment approach to patients with even the most aggressive forms of glioblastoma," said Dr. Courtney Miller, Chief Executive Officer of Myosin Therapeutics. "We are energized by the open communication with the FDA that the Fast Track offers because it will ensure we advance MT-125 as quickly as possible with our patient-centered approach." Source: https://www.prnewswire.com/news-releases/myosin-therapeutics-receives-fda-fast-track-designation-for-mt-125-in-glioblastoma-302591816.html

Irys, the company rebuilding insurance infrastructure from the ground up, today announced a $12.5 million seed round led by Markd, with participation from Deepwork Capital, Florida Opportunity Fund, Ansay & Associates, HICO Ventures, and JMG Capital. The round gives Irys fresh capital to expand engineering, accelerate implementation, and scale distribution partnerships across the U.S and Canada. It also underscores a resurgence of investor confidence in insurance infrastructure, coming shortly after Markd's own $500 million fundraise to back transformative insurtechs. "For 15 years I ran agencies on tech that didn't care if it was usable," said Margeaux Giles, CEO of Irys. "The industry's been trapped in contracts, broken platforms, and empty promises. It's eroded the trust agents fight to build every day with their clients. Irys is how we fix that." Source: https://www.prnewswire.com/news-releases/investors-back-irys-insurtech-with-12-5-million-to-reinvent-insurance-software-302581215.html

The round was led by DeepWork Capital with participation from Florida Opportunity Fund, Lasagna, and Lookout Ventures. DeepWork Capital’s Ben Patz will join Circuitry.ai’s Board of Directors. The company intends to use the funds to expand its go-to-market and engineering teams, deepen integrations with service management platforms, and extend its Autonomous Service Journey framework to more customers in industries such as automotive, heavy equipment, industrial systems, HVAC, and medical devices. Led by Ashok Kartham, Founder & CEO, Circuitry.ai Circuitry.ai delivers an advanced Service Decision Intelligence platform and enterprise AI as a Service (AIaaS) applications specifically designed for manufacturers to enhance service outcomes. By combining AI-driven knowledge, analytics, and automation, Circuitry.ai transforms complex service lifecycle data into precise answers, accurate recommendations, and actionable insights. Its AI workers, including Product Advisor, Service Advisor, Parts Advisor, and Warranty Specialist, significantly boost productivity, increase first-time fix rates, and drive profitable growth through autonomous decision-making. Source: https://www.citybiz.co/article/753858/circuitry-ai-closes-seed-funding/

Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of patients with cardiovascular diseases, today announced that it has completed enrollment in two global, multi-center, Phase 2 clinical trials assessing the safety and efficacy of CRD-750 in both types of chronic heart failure (HFrEF and HFpEF). CRD-750 is an orally-administered phosphodiesterase 9 (PDE9) inhibitor that represents a new mechanism to enhance the natriuretic peptide signaling (NPS) pathway, a clinically-validated pathway for the treatment of patients with heart failure. Cardurion is the first company to bring a PDE9 inhibitor into clinical development for the treatment of chronic heart failure. The CYCLE-1-REF trial (NCT06215911) enrolled approximately 560 patients with HFrEF and is evaluating three doses of CRD-750 compared to placebo. CYCLE-2-PEF (NCT06215586) enrolled approximately 300 patients with HFpEF and is evaluating one dose of CRD-750 compared to placebo. The primary endpoint of both CYCLE clinical trials is the change in N-terminal pro-B-type natriuretic peptide (NT-proBNP), a peptide that is released by the heart in the setting of heart failure. Reduction in NT-proBNP has been used as a biomarker to measure the treatment effect in clinical trials of other approved heart failure therapies. The trials are also evaluating secondary endpoints, including additional biomarkers and the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcomes scale. “The clinical community eagerly awaits the results of the CYCLE clinical trials. Despite recent approvals, a large unmet medical need persists and patients with heart failure continue to experience high rates of morbidity and mortality. PDE9 inhibition is a promising new mechanism in the NPS pathway that may offer an opportunity to improve the standard of care treatment for the millions of patients with both types of chronic heart failure,” said James Udelson, MD, Chief of Cardiology at Tufts Medical Center and Principal Investigator for the CYCLE-1-REF and CYCLE-2-PEF trials. “Completion of enrollment in the CYCLE trials represents a major milestone in our CRD-750 clinical program. Since the founding of Cardurion, our team has believed that the upregulation of PDE9 that occurs in heart failure is a critical element limiting the beneficial clinical effects of the highly validated NPS pathway. Our progress brings us closer to our goal of leveraging PDE9 inhibition to address unmet needs for patients,” said Howard Surks, MD, Chief Medical and Scientific Officer of Cardurion. “It is gratifying for us to implement this large, global clinical program in partnership with the cardiovascular treatment community. We look forward to receiving the Phase 2 results from these clinical trials and presenting them at a future medical meeting.” Source: https://www.globenewswire.com/news-release/2025/08/06/3128280/0/en/Cardurion-Pharmaceuticals-Completes-Enrollment-in-Phase-2-CYCLE-Trials-Evaluating-CRD-750-a-Novel-PDE9-inhibitor-in-Heart-Failure.html

With online scams and data security incidents on the rise, more Americans – especially older adults – are taking proactive steps to store and share their most sensitive information using secure methods. A fast-growing solution is the digital vault: a secure, cloud-based platform for storing and sharing everything from wills and health directives to insurance documents and passwords. AARP’s Fraud Watch Network found that 4 in 10 Americans have lost money to scams or had personal data compromised. The FBI's 2024 Internet Crime Report confirmed the trend, reporting $16.6 billion in total losses, with adults over 60 suffering the highest number of complaints and financial harm. To help address these growing risks, AARP is making available a new product subscription which members can add-on to their membership. Prisidio, an AARP AgeTech Collaborative™ participant, created a digital vault for AARP members that provides a centralized and secure solution for individuals and families to collect and share their most vital documents and information in a more secure way, something that becomes increasingly important as we age. The AARP Digital Vault – powered by Prisidio – can store financial information, legal agreements, mortgage deeds, medical records, plus pictures and videos to ensure loved ones know where to find them when they need to. “A digital vault isn’t just about convenience—it’s about peace of mind and preparedness,” said Sami Hassenyeh, Executive Vice President of Digital Strategy, at AARP. “Today, we offer the digital vault created by Prisidio as a solution that helps members protect what matters most in today’s increasingly digital world.” AARP’s Digital Vault platform goes beyond simple cloud storage. It uses bank-level encryption, smart categorization, and allows users to designate trusted contacts who can access their vault. Whether it’s for estate planning, caregiving coordination, or natural disaster preparedness and daily peace of mind, digital vaults offer a modern way to manage life’s essential information. Read more here: https://www.aarp.org/press/releases/2025-07-30-securing-important-documents-digital-vaults/